Biotech Values

[DewDiligence]

Right. ABBV does, however, have a face-saving incentive to not unduly undermine Imbruvica sales even with sales of 100%-owned regimens: justifying to investors the huge price paid for PCYC.

p.s. With Imbruvica, ABBV's bottom-line economics are essentially the same for sales in the US vs ex-US; the only difference is who books the sales.